PBYI Puma Biotechnology Inc

Price (delayed)

$4.905

Market cap

$236.61M

P/E Ratio

14.86

Dividend/share

N/A

EPS

$0.33

Enterprise value

$270.6M

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights ...

Highlights

Puma Biotechnology's debt has decreased by 2.6% YoY

Puma Biotechnology's equity has surged by 97% YoY but it has decreased by 4.6% QoQ

Puma Biotechnology's quick ratio has decreased by 37% YoY and by 8% from the previous quarter

The net income has contracted by 29% from the previous quarter

Sector: Healthcare

Industry: Biotechnology

Website: http://www.pumabiotechnology.com

Peers: ARRY PFE

Key stats

What are the main financial stats of PBYI

Market

Shares outstanding

48.24M

Market cap

$236.61M

Enterprise value

$270.6M

Valuations

Price to earnings (P/E)

14.86

Price to book (P/B)

4.64

Price to sales (P/S)

1.04

EV/EBIT

9.05

EV/EBITDA

6.53

EV/Sales

1.19

Earnings

Revenue

$226.63M

EBIT

$29.91M

EBITDA

$41.45M

Free cash flow

$35.47M

Per share

EPS

$0.33

Free cash flow per share

$0.74

Book value per share

$1.06

Revenue per share

$4.7

TBVPS

$3.23

Balance sheet

Total assets

$214.15M

Total liabilities

$163.17M

Debt

$110.74M

Equity

$50.98M

Working capital

$44.84M

Liquidity

Debt to equity

2.17

Current ratio

1.46

Quick ratio

1.34

Net debt/EBITDA

0.82

Margins

EBITDA margin

18.3%

Gross margin

73.4%

Net margin

6.8%

Operating margin

11.5%

Efficiency

Return on assets

7.2%

Return on equity

35.4%

Return on invested capital

28.5%

Return on capital employed

25.8%

Return on sales

13.2%

Dividend

Dividend yield

N/A

DPS

N/A

Payout ratio

N/A

PBYI stock price

How has the Puma Biotechnology stock price performed over time

Intraday

-1.11%

1 week

-2.29%

1 month

-8.32%

1 year

86.5%

YTD

13.28%

QTD

-7.45%

Financial performance

How have Puma Biotechnology's revenue and profit performed over time

Revenue

$226.63M

Gross profit

$166.44M

Operating income

$25.98M

Net income

$15.38M

Gross margin

73.4%

Net margin

6.8%

The net income has contracted by 29% from the previous quarter

Puma Biotechnology's net margin has decreased by 26% QoQ

The operating income has contracted by 20% from the previous quarter and by 10% YoY

The operating margin has contracted by 17% from the previous quarter and by 7% YoY

Growth

What is Puma Biotechnology's growth rate over time

Valuation

What is Puma Biotechnology stock price valuation

P/E

14.86

P/B

4.64

P/S

1.04

EV/EBIT

9.05

EV/EBITDA

6.53

EV/Sales

1.19

PBYI's EPS is down by 28% since the previous quarter

Puma Biotechnology's equity has surged by 97% YoY but it has decreased by 4.6% QoQ

PBYI's P/B is 65% lower than its 5-year quarterly average of 13.5 but 7% higher than its last 4 quarters average of 4.4

PBYI's P/S is 31% above its last 4 quarters average of 0.8 but 4.5% below its 5-year quarterly average of 1.1

The revenue has contracted by 3.8% from the previous quarter and by 3.6% YoY

Efficiency

How efficient is Puma Biotechnology business performance

The ROA has soared by 200% YoY but it has decreased by 31% QoQ

PBYI's ROIC has soared by 101% YoY but it is down by 9% QoQ

PBYI's return on sales has surged by 76% year-on-year but it is down by 14% since the previous quarter

Puma Biotechnology's ROE has soared by 65% YoY but it has decreased by 39% from the previous quarter

Dividends

What is PBYI's dividend

DPS

N/A

Dividend yield

N/A

Payout ratio

N/A

There are no recent dividends present for PBYI.

Financial health

How did Puma Biotechnology financials performed over time

The total assets is 31% more than the total liabilities

The company's current ratio fell by 37% YoY and by 7% QoQ

Puma Biotechnology's quick ratio has decreased by 37% YoY and by 8% from the previous quarter

Puma Biotechnology's debt is 117% higher than its equity

Puma Biotechnology's equity has surged by 97% YoY but it has decreased by 4.6% QoQ

Puma Biotechnology's debt to equity has shrunk by 51% YoY but it has increased by 3.8% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.